A class of carbonic anhydrase I - selective activators

A series of ureido and bis-ureido derivatives were prepared by reacting histamine with alkyl/aryl-isocyanates or di-isocyanates. The obtained derivatives were assayed as activators of the enzyme carbonic anhydrase (CA, EC 4.2.1.1), due to the fact that histamine itself has this biological activity....

Full description

Saved in:
Bibliographic Details
Published in:Journal of enzyme inhibition and medicinal chemistry 2017-01, Vol.32 (1), p.37-46
Main Authors: Licsandru, Erol, Tanc, Muhammet, Kocsis, Istvan, Barboiu, Mihail, Supuran, Claudiu T.
Format: Article
Language:English
Subjects:
Alzheimer's disease
Anchoring to zinc-coordinated water
Animals
Anticonvulsants
Biological activity
carbonic anhydrase
Carbonic anhydrase I
Carbonic Anhydrase I - chemistry
Carbonic Anhydrase I - drug effects
Carbonic Anhydrase I - metabolism
Chemical Sciences
Cognitive ability
Crystallography, X-Ray
Enzyme Activators - pharmacology
Histamine
Humans
inhibition mechanism
inhibitors
Isocyanates
Neurodegenerative diseases
occlusion of the active site entrance
out of the active site binding
Physiology
Protein Conformation
Proton Magnetic Resonance Spectroscopy
Spectrometry, Mass, Electrospray Ionization
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A series of ureido and bis-ureido derivatives were prepared by reacting histamine with alkyl/aryl-isocyanates or di-isocyanates. The obtained derivatives were assayed as activators of the enzyme carbonic anhydrase (CA, EC 4.2.1.1), due to the fact that histamine itself has this biological activity. Although inhibition of CAs has pharmacological applications in the field of antiglaucoma, anticonvulsant, anticancer, and anti-infective agents, activation of these enzymes is not yet properly exploited pharmacologically for cognitive enhancement or Alzheimer's disease treatment, conditions in which a diminished CA activity was reported. The ureido/bis-ureido histamine derivatives investigated here showed activating effects only against the cytosolic human (h) isoform hCA I, having no effect on the widespread, physiologically dominant isoform hCA II. This is the first report in which CA I-selective activators were identified. Such compounds may constitute interesting tools for better understanding the physiological/pharmacological effects connected to activation of this widespread CA isoform, whose physiological function is not fully understood.
ISSN:1475-6366
1475-6374
DOI:10.1080/14756366.2016.1232254